middle.news
Immutep Finds Potential Manufacturing Clue and Refocuses Efti Programme
9:01am on Friday 11th of September, 2026 AEST
•
Biotechnology
Read Story
Immutep Finds Potential Manufacturing Clue and Refocuses Efti Programme
9:01am on Friday 11th of September, 2026 AEST
Key Points
Potential manufacturing differences identified between 200 L and 2,000 L efti batches
Future focus narrowed to PD-L1-negative HNSCC and neoadjuvant soft tissue sarcoma
New 200 L manufacturing run contracted
Replacement trials targeted for the second half of 2027, subject to multiple conditions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE